Delisting risk
Virax Biolabs Group (VRAX)
Develops T-cell immune profiling for post-infection syndromes and sells research-use immune reagents.
$2.54
Pre-market−0.02 (−0.78%)
At close$2.56(−1.54%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions3 holders · as of Mar 31, 2026 | 0.18% | 36.8K ADS | |
| Otherremainder | 99.82% | 19.89M ADS |
19.92M ADS as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Mar 2023 annual report; nothing newer is on file here.
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Institutions13F, as of Mar 31, 2026
3 holders · 919.5K shares · 2 new positions · 2 increased · 0 reduced · 4 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 878.8K | 4.41% | +878.8Knew | May 15, 2026 |
| Jump Financial, LLC | 40.7K | 0.20% | +40.7Knew | May 14, 2026 |
| Advisor Group Holdings, Inc. | 20 | 0.00% | 0 | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| James Foster | 24.90% | 13G | Oct 29, 2025 ↗ |
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.